Senseonics Reports $11.7 Million Revenue and $32.3 Million Net Loss for Quarter Ending March 31, 2026

Senseonics Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company achieved total revenue of $11.7 million, a substantial increase from $6.3 million in the same period last year, primarily driven by growth in its U.S. consignment program and demand for its Eversense 365 product. The revenue from related parties, specifically Ascensia, decreased to $2.4 million from $4.4 million, reflecting the transition of commercialization rights back to Senseonics. The gross profit for the quarter rose to $6.9 million, resulting in a gross margin of 59.3%, up from 24.1% a year earlier, largely due to favorable margins on the new product sales and the elimination of revenue share payments to Ascensia.

Despite the revenue growth, Senseonics reported a net loss of $32.3 million for the quarter, compared to a loss of $14.3 million in the prior year. This increase in losses was attributed to a significant rise in selling, general, and administrative expenses, which surged to $30.2 million from $7.7 million, driven by increased marketing efforts and headcount associated with the resumption of U.S. commercialization activities. Research and development expenses also rose to $8.6 million, reflecting ongoing investments in product development, including the Gemini pivotal study.

Operationally, Senseonics has made strategic moves to enhance its market position. The company has transitioned its commercialization activities in the U.S. from Ascensia back to itself, effective January 1, 2026, and is in the process of launching Eversense 365 in several European markets. The company has established new subsidiaries to support patient access and has expanded its sales force to drive product adoption. As of March 31, 2026, Senseonics reported having approximately 300 million covered lives in the U.S. due to positive insurance payor coverage decisions, which is expected to facilitate further growth.

In terms of liquidity, Senseonics had unrestricted cash, cash equivalents, and marketable securities totaling $64.3 million as of the end of the quarter. The company has taken steps to strengthen its financial position, including recent equity offerings that generated approximately $86 million in net proceeds. Additionally, a second amendment to its loan agreement with Hercules Capital has increased its borrowing capacity to $140 million, providing further financial flexibility. Looking ahead, management believes it has sufficient resources to meet its operational needs for the next twelve months, alleviating previous concerns about its ability to continue as a going concern.